Peroxisomal disorders: clinical aspects. 1996

Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
Department of Pediatrics, Gifu University School of Medicine, Japan.

Peroxisomal disorders are divided into two groups from a clinical point of view. Diseases in the first group, peroxisome-deficient disorders (PDD), Zellweger-like syndrome, and isolated deficiencies of peroxisomal beta-oxidation enzymes, are characterized by common clinical features including psychomotor retardation, hypotonia, hepatic dysfunction and visual disturbance. The second group includes diseases with a unique manifestation, such as X-linked adrenoleukodystrophy, hyperoxaluria type I and rhizomelic chondrodysplasia punctata. We investigated clinical aspects and the genetic basis of PDD, and the significance of peroxisomes in the development of human brain. Neuroradiological and neurophysiological studies revealed that thick cortex, colpocephaly and multifocal spikes were characteristic findings of PDD patients in the early infantile period. Cytogenetic studies elucidated the presence of eleven complementation groups among PDD, indicating the presence of eleven pathogenic genes for PDD. Molecular studies elucidated two of these genes, PAF-1 and PXR-1. Immunohistochemical studies clarified that the catalase-positive neurons appeared in the basal ganglia, thalamus, and cerebellum at 28 weeks of gestation, and in the cortex at 35 weeks. Immunopositive glial cells appeared from the deep to superficial white matter with increasing gestational age. These results suggest the important role of peroxisomes in neuronal maturation and myelinogenesis.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002374 Catalase An oxidoreductase that catalyzes the conversion of HYDROGEN PEROXIDE to water and oxygen. It is present in many animal cells. A deficiency of this enzyme results in ACATALASIA. Catalase A,Catalase T,Manganese Catalase,Mn Catalase
D005816 Genetic Complementation Test A test used to determine whether or not complementation (compensation in the form of dominance) will occur in a cell with a given mutant phenotype when another mutant genome, encoding the same mutant phenotype, is introduced into that cell. Allelism Test,Cis Test,Cis-Trans Test,Complementation Test,Trans Test,Allelism Tests,Cis Tests,Cis Trans Test,Cis-Trans Tests,Complementation Test, Genetic,Complementation Tests,Complementation Tests, Genetic,Genetic Complementation Tests,Trans Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018901 Peroxisomal Disorders A heterogeneous group of inherited metabolic disorders marked by absent or dysfunctional PEROXISOMES. Peroxisomal enzymatic abnormalities may be single or multiple. Biosynthetic peroxisomal pathways are compromised, including the ability to synthesize ether lipids and to oxidize long-chain fatty acid precursors. Diseases in this category include ZELLWEGER SYNDROME; INFANTILE REFSUM DISEASE; rhizomelic chondrodysplasia (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC); hyperpipecolic acidemia; neonatal adrenoleukodystrophy; and ADRENOLEUKODYSTROPHY (X-linked). Neurologic dysfunction is a prominent feature of most peroxisomal disorders. Adrenoleukodystrophy, Neonatal,Hyperpipecolic Acidemia,Adrenoleukodystrophy, Autosomal Neonatal Form,Adrenoleukodystrophy, Autosomal, Neonatal Form,Hyperpipecolatemia,Neonatal Adrenoleukodystrophy,Peroxisomal Dysfunction, General,Peroxisomal Dysfunction, Multiple,Peroxisomal Dysfunction, Single,Acidemia, Hyperpipecolic,Acidemias, Hyperpipecolic,Adrenoleukodystrophies, Neonatal,Dysfunction, General Peroxisomal,Dysfunction, Multiple Peroxisomal,Dysfunction, Single Peroxisomal,Dysfunctions, General Peroxisomal,Dysfunctions, Multiple Peroxisomal,Dysfunctions, Single Peroxisomal,General Peroxisomal Dysfunction,General Peroxisomal Dysfunctions,Hyperpipecolic Acidemias,Multiple Peroxisomal Dysfunction,Multiple Peroxisomal Dysfunctions,Neonatal Adrenoleukodystrophies,Peroxisomal Disorder,Peroxisomal Dysfunctions, General,Peroxisomal Dysfunctions, Multiple,Peroxisomal Dysfunctions, Single,Single Peroxisomal Dysfunction,Single Peroxisomal Dysfunctions

Related Publications

Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
March 1991, Minerva pediatrica,
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
April 1999, Neurochemical research,
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
January 1990, Przeglad lekarski,
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
December 1996, Annals of the New York Academy of Sciences,
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
June 1993, American journal of diseases of children (1960),
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
January 1987, Journal of inherited metabolic disease,
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
March 1988, Clinica chimica acta; international journal of clinical chemistry,
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
January 1999, Revista de neurologia,
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
August 1998, Revista de neurologia,
Y Suzuki, and N Shimozawa, and Y Takahashi, and A Imamura, and N Kondo, and T Orii
January 1995, Journal of inherited metabolic disease,
Copied contents to your clipboard!